Difference between revisions of "BioNTech"
(→COVID-19 vaccine: Adding image) |
|||
| Line 13: | Line 13: | ||
==COVID-19 vaccine== | ==COVID-19 vaccine== | ||
| − | The company’s shares shot up 23.4% on Monday morning after the [[ | + | [[File:Covid-19_vaccines.png|300px|right|thumb|Comparing the efficacy of [[Covid-19 vaccine]]s]] |
| + | The company’s shares shot up 23.4% on Monday morning after the [[Covid-19 vaccine]] it is developing with the US pharma giant [[Pfizer]] became the first candidate worldwide to show positive results in phase 3 trials, the crucial final stage of testing. | ||
The total value of BioNTech’s stock is currently $21.9bn (£16.6bn), more than four times that of German national carrier [[Lufthansa]] and a triumph for a company that only made its debut on the US stock market a year ago.<ref>''[https://www.theguardian.com/world/2020/nov/09/biontechs-covid-vaccine-a-shot-in-the-arm-for-germanys-turkish-community "BioNTech's Covid vaccine: a shot in the arm for Germany's Turkish community"]''</ref> | The total value of BioNTech’s stock is currently $21.9bn (£16.6bn), more than four times that of German national carrier [[Lufthansa]] and a triumph for a company that only made its debut on the US stock market a year ago.<ref>''[https://www.theguardian.com/world/2020/nov/09/biontechs-covid-vaccine-a-shot-in-the-arm-for-germanys-turkish-community "BioNTech's Covid vaccine: a shot in the arm for Germany's Turkish community"]''</ref> | ||
| Line 21: | Line 22: | ||
:"Today's positive news is an important step forward in our fight against this pandemic, which has caused suffering and hardship for so many," said the EMA's executive director, Emer Cooke. "Our thorough evaluation means that we can confidently assure EU citizens of the safety and efficacy of this vaccine and that it meets necessary quality standards. However, our work does not stop here. We will continue to collect and analyse data on the safety and effectiveness of this vaccine to protect people taking the vaccine in the [[EU]]."<ref>''[https://www.bbc.co.uk/news/world-europe-55401136 "Covid: Pfizer-BioNTech vaccine approved for EU states"]''</ref> | :"Today's positive news is an important step forward in our fight against this pandemic, which has caused suffering and hardship for so many," said the EMA's executive director, Emer Cooke. "Our thorough evaluation means that we can confidently assure EU citizens of the safety and efficacy of this vaccine and that it meets necessary quality standards. However, our work does not stop here. We will continue to collect and analyse data on the safety and effectiveness of this vaccine to protect people taking the vaccine in the [[EU]]."<ref>''[https://www.bbc.co.uk/news/world-europe-55401136 "Covid: Pfizer-BioNTech vaccine approved for EU states"]''</ref> | ||
{{SMWDocs}} | {{SMWDocs}} | ||
| + | |||
==References== | ==References== | ||
<references/> | <references/> | ||
Revision as of 13:48, 31 December 2020
 BioNTech    | |
|---|---|
 | |
| Founder | • Christoph Huber • Ugur Sahin • Özlem Türeci |
BioNTech is a German biotechnology company dedicated to the development and manufacture of active immunotherapies for a patient-specific approach to the treatment of serious diseases.[1]
Turkish founders
Founded in 2008 by Turkish married scientists Özlem Türeci and Ugur Sahin and the Austrian oncologist Christoph Huber, the company originally set out to develop new types of immunotherapy against cancer, modifying patients’ T cells to target cancer-specific antigens. It researches drugs based on messenger RNA (mRNA) for use as individualised cancer immunotherapies, as vaccines against infectious diseases and as protein replacement therapies for rare diseases, and also engineered cell therapy, novel antibodies and small molecule immunomodulators as treatment options for cancer.
BioNTech developed an mRNA-based human therapeutic for intravenous administration, to bring individualised mRNA-based cancer immunotherapy to clinical trials and to establish its own manufacturing process.[2]
COVID-19 vaccine
The company’s shares shot up 23.4% on Monday morning after the Covid-19 vaccine it is developing with the US pharma giant Pfizer became the first candidate worldwide to show positive results in phase 3 trials, the crucial final stage of testing.
The total value of BioNTech’s stock is currently $21.9bn (£16.6bn), more than four times that of German national carrier Lufthansa and a triumph for a company that only made its debut on the US stock market a year ago.[3]
Approved for use
On 21 December 2020, following approval by the UK's MHRA and the US FDA, the European Medicines Agency (EMA) authorised the Pfizer BioNTech Covid-19 vaccine for the EU's nearly 448 million inhabitants. The EMA said the drug had demonstrated an efficacy of 95% and could be used in people aged 16 and over:
- "Today's positive news is an important step forward in our fight against this pandemic, which has caused suffering and hardship for so many," said the EMA's executive director, Emer Cooke. "Our thorough evaluation means that we can confidently assure EU citizens of the safety and efficacy of this vaccine and that it meets necessary quality standards. However, our work does not stop here. We will continue to collect and analyse data on the safety and effectiveness of this vaccine to protect people taking the vaccine in the EU."[4]
References
This page imported content from Wikipedia on 9 November 2020.Wikipedia is not affiliated with Wikispooks. Original page source here
